Skip to main content
. Author manuscript; available in PMC: 2023 Feb 5.
Published in final edited form as: Mol Cancer Res. 2022 Aug 5;20(8):1183–1192. doi: 10.1158/1541-7786.MCR-22-0111

Figure 5. Co-treatment with PARP inhibitor and cisplatin induces a Fos-driven transcriptional program.

Figure 5.

(A) The Fos-binding motif is enriched in the proximity of BYK + CDDP upregulated genes. The motifs indicated have the highest enrichment within ± 2 kb of the gene body for genes induced by BYK + CDDP.

(B and C) Fos and C-binding motif enrichment correlates to increased gene expression in BYK + CDDP treated HeLa cells. Heatmap (B) and box plot (C) representations of expression of all genes with Fos-binding motif enrichment within ± 2 kb of the gene body under the treatment conditions indicated. Boxes marked with different letters are significantly different from each other (Wilcoxon Signed-Rank test; p < 2.2 × 10−16).

(D) Increased Fos-binding is observed upon co-treatment with BYK + CDDP. ChIP-qPCR showing Fos-enrichment in Vehicle (DMSO) and BYK + CDDP treated HeLa cells. Fos-binding is analyzed in the upstream regulatory regions (<2 kb) of the genes indicated. Each bar represents the mean ± SEM (n = 3; Fisher’s LSD test; * p < 0.05).